PARTNER CONTENT PROVIDED BY ALZHEON, INC.

Preserving Future Memories

Alzheon is poised to introduce the first oral treatment that can slow or stop Alzheimer's disease.

Unprecedented Reduction in Key Alzheimer’s Biomarker for Patients Treated With ALZ-801
camera-iconclock-icon
6 min video | 1 min read

Unprecedented Reduction in Key Alzheimer’s Biomarker for Patients Treated With ALZ-801

John Hey, PhD
by John Hey, PhDChief Scientific Officer, Alzheon, Inc.

A correlation between reduction in plasma p-tau181 and improvement of memory and function has been shown with leading antibodies in patients with Alzheimer’s disease. Alzheon’s ALZ-801 (valiltramiprosate) has resulted in a significant 41% reduction in plasma p-tau at 12 months. This is greater than reductions observed with leading antibodies at 18 months. Watch now to find out what this could mean for patients with Alzheimer’s disease.